Search Videos and More
Showing 1 - 4 of 4 results
News
Immunotherapy Before and After Surgery Improves Outcomes in Head and Neck Cancer
Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without the cancer coming back and higher rates of substantial tumor shrinkage prior to surgery, according to the first interim analysis of a randomized, open-label phase 3 clinical trial led by investigators from Dana-Farber Brigham Cancer Center and Washington University School of Medicine in St. Louis.
News
Head and Neck, Breast, Lung and Survivorship Studies Headline Dana-Farber Research at AACR Annual Meeting 2025
Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck cancer, metastatic breast cancer and lung cancer.
News
Potential Targeted Therapy for Pediatric Brain Cancer Identified by Dana-Farber/Boston Children's Team
An international team of clinical collaborators, led by physician scientists from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, performed a first-ever clinical test of the targeted therapy avapritinib in pediatric and young patients with a form of high-grade glioma.
News
Dana-Farber Researchers Present Findings at 2025 ASCO Genitourinary Cancers Symposium
Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) Cancers Symposium, on February 13-15, 2025, in San Francisco, Calif.